Precision Optics Corporation, Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2014, the first quarter of fiscal 2015. The interim financial statements are unaudited. Precision Optics develops and manufactures optical instruments, predominantly medical devices; approximately 10% of its business is military and industrial products.
Financial performance and liquidity
- Revenue: $830,714, down 8.5% from $907,426 in the prior-year quarter. Management attributed the decline mainly to lower endocoupler and spinal-surgery visualization-system sales, partly offset by rigid endoscopes and initial shipments of new products.
- Profitability: Gross profit fell to $112,138 from $260,234; gross margin contracted to 13.5% from 28.7%. The company reported a net loss of $296,439, versus $210,721. Basic and diluted loss per share were each $0.05 in both periods.
- Expenses: Net research and development expense was $76,712, down 43.1%; selling, general and administrative expense was $347,147, up 3.3%. A $15,282 gain on sale of previously written-off equipment reduced reported operating expenses.
- Cash flow: Cash used in operations was $591,156, compared with $147,033 in the prior-year quarter. Investing activities used $17,305. Financing activities provided $933,572, primarily from the stock offering. Cash increased by $325,111 to $527,491.
- Balance sheet: Current assets were $2.19 million and current liabilities $851,416 at September 30, 2014. Stockholders’ equity was $1.39 million, compared with $740,584 at June 30. The balance sheet reports no debt; the company stated it was not in default on indebtedness.
Material changes and significant transactions
- In July 2014, the company sold 1,717,152 common shares at $0.60 per share. Gross proceeds were $1,030,291, including $50,000 received in June; net proceeds were intended for working capital. The financing increased issued shares from 4,455,134 at June 30 to 6,262,584 at September 30.
- The offering triggered anti-dilution adjustments to outstanding warrants, increasing warrant share counts and lowering exercise prices. The filing details these adjustments; potential dilution should be considered alongside the share issuance.
- Quarterly revenue remained concentrated: Customer A represented 25% of revenue, Customer B 12%, and Customer C 10%. Management said no other customer exceeded 10%.
- Gross margin deterioration reflected lower sales volume and start-up costs and production inefficiencies on several products. R&D expense declined partly because of lower development costs and higher customer reimbursements.
Outlook, risks and controls
- Management expects operating losses to continue until sales reach breakeven and profitable levels. It cited new Microprecision optics, micro medical camera assemblies, and 3D visualization products as potential growth opportunities, but said the timing of customer orders and revenue growth is difficult to predict. No quantified financial guidance was provided.
- The company said it may need additional capital through debt, equity, or a strategic alliance if it cannot reach positive cash flow. Additional equity could dilute shareholders; financing may not be available on acceptable terms. It used $591,156 of operating cash during the quarter and had approximately $298,000 in open purchase-order commitments.
- Management reported disclosure controls and internal control over financial reporting were not effective as of September 30, 2014. It identified material weaknesses involving segregation of accounting duties and inventory valuation; remediation efforts were ongoing, with no assurance they would resolve the weaknesses.
- The company described competitive, regulatory, customer-order-timing, and product-development risks. It reported no material changes to the risk factors in its 2014 Form 10-K and no known pending or threatened litigation expected to have a material impact.
Important facts for investors to verify
- Whether new-product orders and production shipments convert into sustained revenue growth and improved gross margins.
- Cash burn, working-capital needs, and the availability and terms of any future financing.
- The dilution impact of the July share offering, consultant share awards, and warrant adjustments.
- Customer concentration and the timing or continuation of major customer programs.
- Progress in remediating the reported internal-control material weaknesses.